/R E P E A T -- Prometic Plasma Resources announces its participation to the International Plasma Awareness Week/

WINNIPEG, Oct. 6, 2017 /CNW Telbec/ - Prometic Plasma Resources Inc., a subsidiary of Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), today announced its participation to the 2017 International Plasma Awareness Week (IPAW) to be held October 8 ? 14.

This event is held annually and is designed to:

• Raise global awareness about source plasma collection       
• Recognize the contributions of plasma donors to saving and improving lives         
• Increase understanding about lifesaving plasma protein therapies and rare diseases.

Events are held at plasma collection centers in Canada, the U.S. and Europe. This year, Prometic Plasma Resources is inviting a representative from the Canadian Immunodeficiencies Patient Organization (CIPO), http://www.cipo.ca, to visit the plasma center to meet our dedicated plasma donors. CIPO represents patients that have deficiencies with their immune systems. These patients rely on plasma proteins like IGIV to lead normal healthy lives.

"We look forward to giving our donors a chance to meet people that rely on their donations every day. If you are not a donor, come for a tour and learn how easy it is to donate and save lives. If you are a donor, come for a special treat with your donation" said Bill Bees,  

Vice President of Plasma Technologies at Prometic Plasma Resources Inc.    

Media are invited to the plasma center, 137 Innovation Drive, SmartPark, University of Manitoba at 10:30 AM, Tuesday October 10, 2017 for interviews and photo opportunities. For more info visit our web site http://plasma.prometic.com/ or on Tweeter @PrometicPlasma.      

About Prometic Plasma Resources Inc.

PPR is a division of Prometic Life Sciences Inc., a biopharmaceutical corporation with a globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. Prometic is also active in developing its own novel therapeutics products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer, and autoimmune disease/inflammation as well as certain nephropathies.  Prometic is a global business supported by a Head Office in Laval, Canada.

Prometic Plasma Resources is compassionate about saving lives. With every donation collected at our centers, we are able to contribute to the creation of potentially life-saving products that would otherwise not be available. Managed by a team of qualified professionals who have decades of experience in the field of plasma collection, Prometic Plasma Resources strives to create an enjoyable donation experience for each and every donor.  We are continuously seeking opportunities to innovate and improve a donor's visit to Prometic Plasma Resources.

Prometic Plasma Resources center is committed to providing our uncompromising high level of service and attention.
Prometic Plasma Resources (PPR) operates one plasma center in Canada and is licensed by the FDA (Food and Drug Administration) and Health Canada, and is compliant with the European Union regulations and the Plasma Protein Therapeutics Association (PPTA).

About Prometic Life Sciences Inc.

Prometic Life Sciences Inc. (www.prometic.com) is a long-established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development.  Prometic is active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. A number of plasma-derived and small molecule products are under development for orphan drug indications. Prometic also offers its state-of-the-art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. Headquartered in Laval (Canada), Prometic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe and Asia.

Forward Looking Statements    
This press release contains forward-looking statements about Prometic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and Uncertainties related to Prometic's business".  As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.  All amounts are in Canadian dollars unless indicated otherwise.

SOURCE Prometic Plasma Resources Inc.